{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:09:43Z","timestamp":1785168583877,"version":"3.55.0"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2861,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>The hepatotoxic potential of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in patients with underlying chronic liver disease remains controversial. We performed a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial that compared pravastatin (80 mg) to a placebo administered once daily to hypercholesterolemic subjects greater than 18 years of age with at least a 6-month history of compensated chronic liver disease and with a low-density lipoprotein cholesterol (LDL-C) level greater than or equal to 100 mg\/dL and a triglyceride (TG) level lower than 400 mg\/dL. The efficacy was determined by the percentage change in LDL-C [along with the total cholesterol (TC), high-density lipoprotein cholesterol, and TG] from the baseline to week 12. The safety was analyzed by the proportion of subjects who developed at least 1 alanine aminotransferase (ALT) value greater than or equal to 2 times the upper limit of normal for those with normal ALT at the baseline or a doubling of the baseline ALT for those with elevated ALT at the baseline during 36 weeks of treatment. A total of 630 subjects were screened, and 326 subjects were randomized; nonalcoholic fatty liver disease was present in 64%, and chronic hepatitis C was present in 23%. In the intent-to-treat population, pravastatin (80 mg\/day) significantly lowered the mean LDL-C, TC, and TG values at week 12 and at other times (weeks 4, 8, 24, and 36) in comparison with the placebo. The incidence of subjects who met the primary prespecified ALT event definition was lower in the pravastatin group at all times over the 36 weeks of therapy in comparison with the placebo group, although the difference was not statistically significant. No differences were seen on the basis of the baseline ALT values or among the different liver disease groups.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>High-dose pravastatin (80 mg\/day) administered to hypercholesterolemic subjects with chronic liver disease significantly lowered LDL-C, TC, and TGs in comparison with the placebo and was safe and well tolerated. The concern over an increased potential for statin-induced hepatotoxicity in patients with chronic liver disease appears to be lessened on the basis of these results.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.21848","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T20:48:14Z","timestamp":1186001294000},"page":"1453-1463","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":248,"title":["Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial"],"prefix":"10.1097","volume":"46","author":[{"given":"James H.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Zweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jean","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Medoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Belder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20241201","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0735-1097(99)00525-2","article-title":"The evolving role of statins in the management of atherosclerosis.","volume":"35","author":"Vaughan","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R2-19-20241201","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","article-title":"Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.","volume":"130","author":"Ho","year":"2006","journal-title":"Gastroenterology"},{"key":"R3-19-20241201","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1089-3261(03)00024-2","article-title":"Hepatotoxicity of hypolipidemic drugs.","volume":"7","author":"Parra","year":"2003","journal-title":"Clin Liver Dis"},{"key":"R4-19-20241201","first-page":"498","article-title":"Toxicity of the HMGcoenzyme A reductase inhibitor, lovastatin, to rabbits.","volume":"248","author":"Kornbrust","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"R5-19-20241201","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1592\/phco.24.6.584.34738","article-title":"Statins and liver toxicity: a metaanalysis.","volume":"24","author":"de Denus","year":"2004","journal-title":"Pharmacotherapy"},{"key":"R6-19-20241201","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.clinthera.2006.01.005","article-title":"Statinrelated adverse events: a metaanalysis.","volume":"28","author":"Silva","year":"2006","journal-title":"Clin Ther"},{"key":"R7-19-20241201","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1161\/01.CIR.0000017634.00171.24","article-title":"Safety and tolerability of pravastatin in longterm clinical trials: Prospective Pravastatin Pooling (PPP) Project.","volume":"105","author":"Pfeffer","year":"2002","journal-title":"Circulation"},{"issue":"Suppl 1","key":"R8-19-20241201","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0002-9149(00)00946-2","article-title":"Defining patient risks from expanded preventive therapies.","volume":"85","author":"Tolman","year":"2000","journal-title":"Am J Cardiol"},{"key":"R9-19-20241201","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S0002-9149(02)02355-X","article-title":"The liver and lovastatin.","volume":"89","author":"Tolman","year":"2002","journal-title":"Am J Cardiol"},{"key":"R10-19-20241201","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2165\/00002018-200023030-00003","article-title":"Comparative tolerability of the HMGCoA reductase inhibitors.","volume":"23","author":"Farmer","year":"2000","journal-title":"Drug Saf"},{"key":"R11-19-20241201","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.dld.2006.04.013","article-title":"Atorvastatin associated liver disease.","volume":"38","author":"Clarke","year":"2006","journal-title":"Dig Liver Dis"},{"key":"R12-19-20241201","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.amjmed.2005.02.008","article-title":"Evaluation of cases of severe statinrelated transaminitis within a large health maintenance organization.","volume":"118","author":"Charles","year":"2005","journal-title":"Am J Med"},{"key":"R13-19-20241201","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders.","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"key":"R14-19-20241201","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1002\/lt.20204","article-title":"Liver transplantation for acute liver failure from drug induced liver injury in the United States.","volume":"10","author":"Russo","year":"2004","journal-title":"Liver Transpl"},{"key":"R15-19-20241201","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijcard.2004.03.053","article-title":"Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates.","volume":"101","author":"Baessler","year":"2005","journal-title":"Int J Cardiol"},{"key":"R16-19-20241201","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/archinte.163.6.657","article-title":"Safety and statin therapy: reconsidering the risks and benefits.","volume":"163","author":"Gotto","year":"2003","journal-title":"Arch Intern Med"},{"issue":"Suppl 3","key":"R17-19-20241201","doi-asserted-by":"crossref","first-page":"III3","DOI":"10.1002\/clc.4960261503","article-title":"Risks and benefits of continued aggressive statin therapy.","volume":"26","author":"Gotto","year":"2003","journal-title":"Clin Cardiol"},{"key":"R18-19-20241201","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1331\/154434506778073637","article-title":"Safety issues with statins.","volume":"46","author":"Talbert","year":"2006","journal-title":"J Am Pharm Assoc (Wash DC)"},{"issue":"Suppl 1","key":"R19-19-20241201","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2005.12.005","article-title":"Statins, cardiovascular disease, and drug safety.","volume":"97","author":"Gotto","year":"2006","journal-title":"Am J Cardiol"},{"issue":"Suppl 1","key":"R21-19-20241201","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.amjcard.2005.12.014","article-title":"An assessment of statin safety by hepatologists.","volume":"97","author":"Cohen","year":"2006","journal-title":"Am J Cardiol"},{"key":"R22-19-20241201","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1053\/j.gastro.2004.02.015","article-title":"Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.","volume":"126","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"R23-19-20241201","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.20671","article-title":"Statins and hepatotoxicity: focus on patients with fatty liver.","volume":"41","author":"Chalasani","year":"2005","journal-title":"Hepatology"},{"key":"R24-19-20241201","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00000441-200502000-00002","article-title":"Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.","volume":"329","author":"Vuppalanchi","year":"2005","journal-title":"Am J Med Sci"},{"key":"R25-19-20241201","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.cgh.2006.03.014","article-title":"Incidence of statin hepatotoxicity in patients with hepatitis C.","volume":"4","author":"Khorashadi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R26-19-20241201","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.amjcard.2005.06.071","article-title":"Experience with statin use in patients with chronic hepatitis C infection.","volume":"96","author":"Gibson","year":"2005","journal-title":"Am J Cardiol"},{"key":"R27-19-20241201","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2004.01.008","article-title":"Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study.","volume":"174","author":"Rallidis","year":"2004","journal-title":"Atherosclerosis"},{"key":"R28-19-20241201","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00007890-199610150-00011","article-title":"Hyperlipidemia after liver transplantation: natural history and treatment with the hydroxylmethylglutarylcoenzyme A reductase inhibitor pravastatin.","volume":"62","author":"Imagawa","year":"1996","journal-title":"Transplantation"},{"key":"R29-19-20241201","first-page":"890","article-title":"Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia.","volume":"15","author":"Kurihara","year":"1993","journal-title":"Clin Ther"},{"key":"R30-19-20241201","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S0168-8278(02)00006-5","article-title":"Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers.","volume":"36","author":"Ritzel","year":"2002","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"R31-19-20241201","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"R32-19-20241201","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0939-4753(04)80008-5","article-title":"Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits.","volume":"14","author":"Anfossi","year":"2004","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"R33-19-20241201","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14740338.1.2.159","article-title":"The rational use of potentially hepatotoxic medications in patients with underlying liver disease.","volume":"1","author":"Lewis","year":"2002","journal-title":"Expert Opin Drug Saf"},{"key":"R34-19-20241201","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0002-9149(03)00026-2","article-title":"Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day.","volume":"91","author":"Rosenson","year":"2003","journal-title":"Am J Cardiol"},{"key":"R35-19-20241201","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"R36-19-20241201","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/009286159502900107","article-title":"Sample size for therapeutic equivalence based on confidence interval.","volume":"29","author":"Lin","year":"1995","journal-title":"Drug Inf J"},{"key":"R37-19-20241201","first-page":"57","article-title":"Longterm experience with pravastatin in clinical research trials.","volume":"15","author":"McGovern","year":"1993","journal-title":"Clin Ther"},{"key":"R38-19-20241201","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"R39-19-20241201","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.","volume":"335","author":"Sacks","year":"1996","journal-title":"N Eng J Med"},{"key":"R40-19-20241201","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.","volume":"339","year":"1998","journal-title":"N Engl J Med"},{"key":"R41-19-20241201","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S0025-7125(05)70287-X","article-title":"Druginduced liver disease.","volume":"84","author":"Lewis","year":"2000","journal-title":"Med Clin North Am"},{"key":"R42-19-20241201","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1161\/01.CIR.101.2.207","article-title":"Current perspectives on statins.","volume":"101","author":"Maron","year":"2000","journal-title":"Circulation"},{"key":"R43-19-20241201","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1001\/archinte.160.15.2273","article-title":"Longterm safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors. The role of metabolismmonograph for physicians.","volume":"160","author":"Bottorff","year":"2000","journal-title":"Arch Intern Med"},{"issue":"Suppl 1","key":"R44-19-20241201","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review.","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"R45-19-20241201","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00042737-200308000-00014","article-title":"Autoimmune hepatitis revealed by atorvastatin.","volume":"15","author":"Pelli","year":"2003","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R46-19-20241201","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/00004836-200609000-00018","article-title":"Autoimmune hepatitis triggered by statins.","volume":"40","author":"Alla","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"R47-19-20241201","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1468-3083.2006.01838.x","article-title":"Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.","volume":"21","author":"Noel","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R48-19-20241201","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipidlowering drugs.","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"R49-19-20241201","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/hep.20548","article-title":"Serum alanine aminotransferase in skeletal muscle diseases.","volume":"41","author":"Nathwani","year":"2005","journal-title":"Hepatology"},{"key":"R50-19-20241201","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1053\/j.gastro.2004.03.030","article-title":"Are patients with elevated liver tests at increased risk of druginduced liver injury?","volume":"126","author":"Russo","year":"2004","journal-title":"Gastroenterology"},{"key":"R52-19-20241201","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/pds.1209","article-title":"Hys law, the Rezulin rule, and other predictors of severe druginduced hepatotoxicity: putting riskbenefit into perspective.","volume":"15","author":"Lewis","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 1","key":"R53-19-20241201","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/jlts.2001.29167","article-title":"Longterm management of the liver transplant patient: diabetes, hyperlipidemia, and obesity.","volume":"7","author":"Reuben","year":"2001","journal-title":"Liver Transpl"},{"key":"R54-19-20241201","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00228-002-0541-7","article-title":"Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.","volume":"58","author":"Simonson","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"R55-19-20241201","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1053\/j.gastro.2004.08.058","article-title":"Statininduced hepatotoxicity.","volume":"127","author":"Chalasani","year":"2004","journal-title":"Gastroenterology"},{"key":"R56-19-20241201","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/hep.21248","article-title":"Statins and hepatic steatosis: perspectives from the Dallas Heart Study.","volume":"44","author":"Browning","year":"2006","journal-title":"Hepatology"},{"key":"R57-19-20241201","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0002-9343(94)90090-6","article-title":"Efficacy and safety of pravastatin in the longterm treatment of elderly patients with hypercholesteroloemia.","volume":"96","author":"Santinga","year":"1994","journal-title":"Am J Med"},{"key":"R58-19-20241201","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0002-9343(99)80182-X","article-title":"Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.","volume":"99","author":"Raskin","year":"1995","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"R59-19-20241201","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.amjcard.2005.12.016","article-title":"Benefit versus risk in statin treatment.","volume":"97","author":"Guyton","year":"2006","journal-title":"Am J Cardiol"},{"key":"R60-19-20241201","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.cgh.2006.04.020","article-title":"Statins for hyperlipidemia in patients with chronic liver disease. Are they safe?","volume":"4","author":"Vuppalanchi","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R61-19-20241201","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACCAHANHLBI clinical advisory on the use and safety of statins.","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 1","key":"R62-19-20241201","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.amjcard.2005.12.006","article-title":"Statin safety: an overview and assessment of the data2005.","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"R63-19-20241201","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.4065\/81.9.1225","article-title":"The safety of aggressive statin therapy: how much can lowdensity lipoprotein cholesterol be lowered?","volume":"81","author":"Jacobson","year":"2006","journal-title":"Mayo Clin Proc"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21848","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200711000-00019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T08:09:42Z","timestamp":1733040582000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200711000-00019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,11]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21848","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1095039.550026","asserted-by":"object"}]},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,11]]}}}